CMA
CTKB icon

Cedar Mountain Advisors’s Cytek Biosciences CTKB Stock Holding History

Cedar Mountain Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21
Closed -$106 – 1165
2025
Q4 		$106 Buy
+21
New +$98 ﹤0.01% 708

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cedar Mountain Advisors's CTKB Position: Q1 2026 in Review

Cedar Mountain Advisors sold out of Cytek Biosciences (CTKB) in Q1 2026, closing a stake of 21 shares — an estimated $106 sold.

Cedar Mountain Advisors first reported a position in CTKB in Q4 2025 and held it in 1 quarter. The position peaked at $106 in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Cedar Mountain Advisors reported no remaining Cytek Biosciences position as of Q1 2026 after selling out during the quarter.
  • Cedar Mountain Advisors sold 21 Cytek Biosciences shares in Q1 2026, an estimated $106.
  • Cedar Mountain Advisors first reported a position in Cytek Biosciences in Q4 2025 and held it in 1 quarter.
  • Cedar Mountain Advisors's Cytek Biosciences position peaked at $106 in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Cedar Mountain Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.